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hile cancer treatment improved dramatically during
the past decades and nowadays allows cures for many
previously fatal cases, in a significant number of
patients therapy still fails. An important reason for this variability
in therapy success is inter-tumoral heterogeneity, which is a
characteristic of most if not all tumor categories. Hence, it is
generally believed that future therapeutic approaches should be
more patient-tailored and take into account the specific molecular
and cellular characteristics of the individual tumors. Along these
lines, genetic analysis is now a clinical routine for different types
of cancers and allows identification of patient-specific driver
oncogenes that serve as relevant therapeutic targets. Unfortu-
nately, genome-based drug selection is not feasible for tumors
which are driven by mutated but undruggable targets and have an
otherwise low mutational burden, a characteristic of many
pediatric sarcomas and leukemias.
An example for this class of tumors is rhabdomyosarcoma
(RMS), which is the most common soft-tissue sarcoma in chil-
dren and is composed of several histological subtypes, all having
cells with characteristics of a propensity for skeletal-muscle dif-
ferentiation. The two main histological RMS subtypes, alveolar
(ARMS) and embryonal (ERMS), are characterized by distinct
genetic alterations. Most ARMS cases are associated with specific
translocations, generating PAX3-FOXO1 or PAX7-FOXO1 fusion
transcription factors that act as the main drivers of tumorigenesis.
ERMS cases, in contrast, do not contain these translocations and
have a more heterogeneous genetic landscape. One important
subgroup is associated with mutational activation of the RAS-
pathway. Based on these molecular characteristics, RMS is sub-
classified into fusion-positive (FP-RMS) and fusion-negative (FN-
RMS) RMS. In both FP-RMS and FN-RMS, the number of driver
oncogenes that hold the potential for druggability is very low1–3.
Despite the great progress that has been made in RMS treatment
by optimizing conventional therapies, up to 30 percent of patients
still have dismal outcome and no targeted therapy has entered
into clinical practice so far4. This situation highlights the unmet
medical need to address alternative routes that aid cancer-drug
treatment decisions.
An alternative option for identification of drugs effective
against mutationally quiet tumors is direct and unbiased testing
of compounds on freshly isolated, patient-derived cancer cells. In
general, patient cells can be propagated in mice as patient-derived
xenografts (PDX) or grown in vitro under suitable culture con-
ditions in 2D or 3D. While PDX models constitute an important
tool for expansion of patient-derived biopsies and, at least during
early passages, closely resemble the original tumor specimen at
the morphological and molecular level, they might not be
affordable in terms of cost and space for many laboratories and
are unsuitable for large high throughput drug testing5,6. For large
phenotypic screenings with drug libraries, in vitro cultures of
cancer cells are more suitable. In case of leukemia as well as some
carcinoma entities such screening approaches have proven to
produce data of clinical utility7–11. Importantly however, opti-
mized protocols for primary cancer cell cultures have been
established for only a small number of entities and not yet for
sarcoma.
Here, we set out to develop a functional predictive preclinical
toolkit which combines the use of PDX and primary cultures for
RMS. In this respect, we present the systematic development of
optimized culture conditions for PDX-derived primary RMS cells.
Importantly, we detect subtype specific demands on culture
parameters such as presence or absence of bFGF and find that
traditional culture conditions with presence of serum have a toxic
effect on primary RMS cells, leading to the outgrowth of resistant
clones. Comprehensive molecular characterization demonstrates
that cultured cells are stable both at the genomic and genetic level
under these conditions. Additionally, by performing drug screens
we show the feasibility of our platform to pinpoint patient-
specific pharmacological vulnerabilities with a high-fidelity pre-
diction of the in vivo response and describe an AKT-inhibitor
sensitivity of specific samples. Finally, we show that established
culture conditions allow propagation and drug-profiling of cells
directly isolated from patient tumors, considerably accelerating
the procedure. Our platform therefore holds the promise to be a
valid tool for prioritizing actionable drug targets for RMS in a
clinical setting.
Results
Culture conditions for PDX-derived primary RMS cells. To set
up a cell culture system that closely preserves the phenotypic and
molecular characteristics of cells in the parental tumor, we fol-
lowed the scheme depicted in Fig. 1a. We used a collection of 20
RMS PDX tumors (12 FN-RMS and 8 FP-RMS), either estab-
lished on our own with a success rate comparable to previous
reports12 or in one of the three collaborating institutions (Sup-
plementary Fig. 1A, B)12. Then, we first aimed to determine the
optimal culture conditions supporting growth of the PDX-derived
primary cells (PPCs) in vitro. At least two independent pieces
from each PDX model were re-transplanted s.c. into NSG mice
and grown up to 1 cm3, followed by tumor isolation, dissociation
into a single cell suspension and culture in 96-well plate format.
We compared 18 different culture conditions by combining three
media (DME and F10 medium both supplemented with 10% heat
inactivated fetal bovine serum [FBS] and Neurobasal [NB]
medium supplemented with serum replacement B-27) with three
types of adhesion substrates (no coating, Matrigel and Gelatin),
each in the presence or absence of growth factors (GF) (EGF plus
bFGF). Cell viability/proliferation was determined by WST-1
assay (normally within 1-3 weeks), and cell morphology, differ-
entiation status and contamination with mouse stromal cells was
assessed by microscopy (Fig. 1b). Differentiation was monitored
by Myosin Heavy Chain (MHC) expression (Supplementary
Fig. 1C), while mouse cells were identified by the punctate DAPI-
staining pattern of their nuclei13 (Supplementary Fig. 1C). The
analysis revealed that F-10 medium was not effective in sup-
porting PPC growth in most cases and therefore was not studied
further (Fig. 1b and Supplementary Fig. 1D). In contrast, NB
conditions supported growth of cells from most PDX tumors,
especially in combination with an adhesion substrate, and also
exhibited the lowest percentage of mouse contamination across
the entire set of samples tested (Fig. 1b and Supplementary
Fig. 1D). DMEM conditions typically yielded high cell viability
scores independently from the coating matrix or presence of GFs
(Fig. 1b and Supplementary Fig. 1D). Importantly however,
morphological analysis revealed that cells in DMEM often had an
increased size and were rich in stress-fibers, suggesting that this
conditions does not support continuous proliferation. Further-
more, DMEM cultures were enriched with mouse cell con-
taminants, which completely overtook the culture in four cases
(Fig. 1b, right panel).
Although cell differentiation was highly affected by the different
culture conditions, it remained below 10% in most of the samples
(8 out of 13 PPCs) consistent with the low fraction of terminally
differentiated cells observed in primary RMS tumors14,15 (Fig. 1b).
Nevertheless, in a few PPCs such as SJRHB010463_X16 (PAX3-
FOXO1 positive), SJRHB010468_X1C and SJRHB013757_X2
(both PAX7-FOXO1-positive), the percentage of MHC+ cells
exceeded 30% in some conditions, a phenomenon that was visible
either after short-term culture or at later passages (Fig. 1b,
Supplementary Fig. 2A) and that highlights the inherent myogenic
differentiation potential of some RMS.
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To further validate these findings, we next compared the long-
term proliferation rate of PPCs in DMEM and NB medium.
Counting of cell numbers of 6 FP-RMS and 5 FN-RMS cultures
over a period of 1-2 months at every passage revealed that in 10
out of 11 cases (91%), NB-cultured cells continuously proliferated
with an exponential growth rate, whereas cell counts in DMEM
decreased over time starting already at passage 1 or 2 (Fig. 1c, d
and Supplementary Fig. 2B). Only SJRHB13758_X2C cells could
easily be propagated in DMEM with a growth kinetic indis-
tinguishable from the one in NB medium, reflecting the high
take-rate and aggressiveness of this particular tumor observed
in vivo (Fig. 1d and Supplementary Fig. 2B). Overall, this initial
test series resulted in highly efficient (17/20 PDX) generation of
PPCs and only in case of RMS-ZH002, RMS-ZH005 and RMS-
AMS007 culture establishment failed. In these latter cases we
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ROCK and TGFβ pathway inhibitors in combination with the
additives described above. Interestingly, these conditions allowed
establishment PPCs in all these cases (Fig. 1e).
The optimized medium conditions also allowed propagation of
PPCs as spheroids in a 3D culture system, with both size and cell
numbers in spheroids increasing over time (Supplementary
Fig. 3A, B). Immunohistochemical (IHC) characterization of
7 days old spheroids confirmed that the majority of cells was
negative for cleaved Caspase-3 and expressed RMS markers
(Myogenin and AP2β) (Supplementary Fig. 3A). Furthermore, we
detected increased levels of the hypoxia marker Glut-1 in the
center of large spheroids, indicating presence of an oxygen-
gradient from the outside towards the inside of the spheres as
expected (Supplementary Fig. 3A).
Finally, to evaluate whether in vitro culture in NB medium
affects tumorigenicity of cells in vivo, we injected 5 × 106 RMS-
ZH004 cells from in vitro cultures and dissociated parental PDX
into NSG mice. In both models the engraftment rate was 100%
and tumor growth as well as survival of tumor-bearing mice were
very similar (Fig. 1f).
Altogether, these findings indicate that our platform can
readily capture heterogeneity in culture requirements among
different tumors and identified NB medium in combination with
a matrix support as the optimal condition that outperforms
conventional cell line protocols.
Culture condition dependencies distinguish subgroups of
RMS. To better characterize our culture protocol, we aimed next
to unravel the role of individual media constituents in more
detail.
First, we assessed the contribution of GFs to cell viability and
proliferation and calculated the ratio of cell viability in presence and
absence of GFs (Fig. 2a). Remarkably, while GFs stimulated growth of
FP-RMS, in FN-RMS they either were inert or dramatically impaired
cell viability (SJRHB012_YC, SJRHB012_ZC, SJRHB011_XC and
SJRHB011_YC), demonstrating differential GF demands among
PPCs (Fig. 2a–c, Supplementary Figs. 1D and 4A). To identify the
responsible GF, we evaluated the proliferation rate of GF-stimulated
(SJRHB013759_X1C) and -inhibited (SJRHB011_YC, SJRHB012_YC
and SJRHB012_ZC) PPCs under all possible permutations (Fig. 2c
and Supplementary Fig. 4B). Notably, this analysis identified bFGF as
the major player affecting proliferation (Fig. 2c and Supplementary
Fig. 4B). Taken together, while these data confirm the well-known
role of FGF signaling pathways for RMS cell proliferation, they also
unravel a novel and unexpected anti-proliferative effect of bFGF in
some FN-RMS.
Second, we aimed to determine the component(s) in the DMEM
mixture which are detrimental to cell growth by measuring
proliferation of four PPCs in both DMEM or NB-based media
supplemented with either B-27, FBS or the combination of both
(Fig. 2d and Supplementary 4C,D). This revealed that FBS limited
cell growth in all PPC cultures irrespective of medium (Fig. 2d and
Supplementary Fig. 4C, D).
Importantly, in DMEM cultures of two tumors (SJRHB012_YC
and SJRHB012_ZC) we observed outgrowth of a few clones in
DMEM medium (DMEM_clones), which then could be propa-
gated to confluent monolayers within 1-2 months (Supplemen-
tary Fig. 4E, F). When transplanted into mice, both NB cultured
cells and the DMEM clones were tumorigenic. Though the NB
cultured cells and DMEM clones displayed similar growth
kinetics with no significant differences in animal survival for
SJRHB012_YC cells (Supplementary Fig. 4G), the DMEM clones
from SJRHB012_ZC showed a more heterogeneous in vivo
growth pattern and tumorigenic behavior than the corresponding
NB cultured cells (Supplementary Fig. 4H). Thus, cells cultured in
DMEM require a selection and/or adaptation process to re-gain
proliferation which is not always homogenous in vivo.
Overall, this analysis identifies a difference in response to FGF
pathway activation between FN- and FP-RMS and also implicates
serum as an adverse component for PPC long-term proliferation
(Fig. 2e).
Molecular and histological characterization of PDXs and PPCs.
To assess whether our culture conditions exert a clonal selection
pressure16, we performed an in-depth molecular analysis of all
matched PDX tumors and PPCs. First, we compared global DNA
copy number alterations in matched PDX tumors and PPCs
(passage<11) using array-CGH (aCGH). Overall, we detected a
high level of concordance between PDXs and PPCs (Fig. 3a and
Supplementary Fig. 5). Nevertheless, in accordance with previous
studies, we also noticed some focal differences in DNA copy
numbers between PDX and corresponding PPCs which were
more pronounced in DMEM-derived clones (Fig. 3a).
Next, we analyzed the mutational landscape in PDXs and
corresponding PPCs by exome sequencing. If available, we also
compared data from PDX and PPC with patient germline data.
This comparison confirmed that all somatic mutations identified
in the PDX are also present in matched PPCs (Fig. 3b). The
mutations found in our cohort reflect the common mutational
spectrum of RMS. In FN-RMS we detected recurrent mutations in
the RAS pathway, including FGFR4, NRAS and HRAS mutations,
and TP53. Importantly, we also detected a close relationship
Fig. 1 2D and 3D culture platform of PPCs. aWorkflow used to set up a RMS pre-clinical drug profiling platform. Briefly, PDXs were established from small
RMS biopsies and first enzymatically dissociated to derive PPCs, followed by a culture condition screen (see text). DNA-sequencing and aCGH analysis
were performed on both PDXs and paired PPCs to generate a sample collection with annotated genomic information. Finally, a high-throughput drug screen
was conducted on each PPC cultivated under optimal culture conditions and top drug candidates were further validated in vivo on the original PDXs.
b Culture optimization of indicated PPCs. Heat map depicting cell viability scores (n= 2–5 biological replicates), differentiation status (n= 2–3 biological
replicates) and quantification of contamination with mouse stroma cells (n= 2–3 biological replicates) after short-term culture (1–3 weeks) of PPCs is
shown. nd, not determined due to either low number of surviving cells or high fraction of cell loss during washing steps. c Growth curves of indicated PPCs
cultured in DMEM on uncoated plates (black line) or in NB+GF on matrigel (red line). Cell number was normalized to day of seeding and is expressed in a
log2 scale. (Mean ± range; n= 2 biological replicates). d Graph summarizing the proliferation rate of 11 PPCs under optimal and standard DMEM
conditions. Data express the percentage of cells after 5 passages relative to day 0 in a log2 scale (n= 2–3 biological replicates). The dotted line indicates
the cell number at day 0. e, left panel, Viability of the human cell fraction in PPCs from RMS-AMS007 PDXs cultured under indicated conditions (Mean ±
range; n= 2 biological replicates). e, right panel, Viability of PPCs from RMS-AMS007 cultured in indicated media supplemented with ROCK- (Y-27632)
and/or TGFβ- (A83-01) inhibitors (Mean ± sd; n= 3 biological replicates; two-way ANOVA with Tukey’s multiple comparisons test). f, left panel, Tumor
growth kinetics of RMS-ZH004 PDX (blue, n= 3 biological replicates) and passage 4 CDX (green, n= 5 biological replicates). (Mean ± sem). f, right panel,
Histogram indicating the day (d) of sacrifice of individual CDX- and PDX-bearing mice (gray dots) when tumors reached ~1000 mm3. (Mean ± sd; two-
tailed paired t-test; NS, not significant;). Source data are provided as source data file.
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Fig. 2 Culture condition dependencies distinguish subgroups of RMS. a Heat map displaying the ratio of cell viability scores (as calculated from data
shown in Fig. 1b and corrected for mouse contamination) in presence and absence of GFs (+/- GF) for FN-RMS (left) and FP-RMS (right) PPCs. Light and
dark purple colors indicate a negative and positive influence of the GF on cell viability, respectively. White color represents a range of negligible effect.
b Representative bright-field images of indicated cells at passage 1 cultivated with or without GF stimulation. Scale bar, 200 μm. c Assessment of GF
dependency for long-term proliferation of GF-inhibited (SJRHB012_YC, upper panel) and GF-stimulated (SJRHB013759_X1C, lower panel) cells. Each data
point is expressed as percentage of day 0. (Mean ± range; n= 2 biological replicates; two-way ANOVA with Tukey’s multiple comparisons test). c, right
panel, Representative light-microscopy images of the respective cells taken at passage 2. 100X magnification. d Histograms displaying cell counts over
time for two PPC lines (RMS-ZH004_XC, SJRHB012_YC) cultivated under indicated conditions. -GF and +GF indicate the absence and presence of growth
factors in the culture, respectively. (Mean ± range; RMS-ZH004_XC 0-14 days n= 3 biological replicates, RMS-ZH004_XC 21 days and SJRHB012_YC,
n= 2 biological replicates; two-way ANOVA with Dunnett’s multiple comparison test). e Heat map summarizing growth conditions found to be optimal for
indicated PPCs. NB, NB medium supplemented with 2xB27, Adv.DMEM/F12, Adv.DMEM/F12 medium supplemented with 0.75xB27, Y-27632, A83-01
and N-acetylcysteine. Source data are provided as source data file.
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between the mutational status of TP53 and the cellular response
to idasanutlin, a MDM2-P53 interaction antagonist (Supplemen-
tary Fig. 6A), suggesting that increasing P53 protein levels in cells
with non-mutant TP53 remains an attractive therapeutic strategy.
In FP-RMS the number of detected somatic SNVs was generally
much lower. Expression of PAX3/7-FOXO1 fusion proteins was
validated in all FP-RMS cultures by Western blot (Supplementary
Fig. 6B). We then used the genewise target coverage of the exome
seq data to identify focally amplified genes and matched the
findings with the aCGH data. We detected amplifications of
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We also determined the stability of the models at both the
epigenetic and genetic level. For the former we measured
methylation profiles of 15 PDX/PPC pairs and used 8 common
RMS cell lines (4 ARMS and 4 ERMS) as comparison. Principle
component analysis (PCA) revealed that in 13 out of 15 cases
PDXs and corresponding PPCs have similar methylation profiles
and only two of the PDX/PPC pairs (SJRHB013759_X1 and IC-
pPDX-35) showed a more divergent methylation pattern (Fig. 3c).
Importantly, conventional cell lines clustered separately display-
ing much higher methylation levels at multiple sites.
To assess genetic stability we compared the number of exonic
SNVs present in PDX and PPCs, respectively. Interestingly, in
most pairs the number of SNVs was very similar (Fig. 3d). Only
in SJRHB13758_X2C cells, we noticed a high number of unique
SNVs that were not present in the parental PDX, indicative of
genetic instability in the cultured cells.
To test whether histological RMS features are preserved in our
models, we generated s.c. xenografts with passage 4-6 PPC cells (cell-
derived xenografts; CDX) and compared their histological character-
istics with the PDX and original patient tumors, if available. Tumor
sections were assessed for cell and tissue morphology by haematox-
ylin and eosin (H&E) staining and for presence of cells with skeletal
muscle differentiation by immunohistochemical detection of DES-
MIN and MYOGENIN. Impressively, both PDX and CDX show
characteristic RMS architecture and a degree of MYOGENIN and
DESMIN positivity, which is in line with published data showing that
number of MYOGENIN positive cells discriminates ARMS from
ERMS (Supplementary Fig. 7A, B).
Altogether, these findings showed that PPCs are epigenetically
and genetically stable and faithfully recapitulate tumor histology
when transplanted in vivo.
In vitro compound screen with PPCs. We next asked whether
PPC cultures would represent a suitable pre-clinical model to
unveil drug sensitivities in individual tumors. Therefore, we
applied an in vitro proof-of-concept high-throughput screen
employing a compound library containing 204 drugs which
contained both Food and Drug administration (FDA)-approved
drugs and small molecules in clinical development, covering a
range of functional classes of targets, as well as standard che-
motherapeutics used for RMS therapy (Supplementary Table 2).
A panel of 17 PPCs (10 FN-RMS and 7 FP-RMS) and four
established cell lines (FN-RMS cell lines RD and RH36 and FP-
RMS cell lines Rh4 and Rh30) were cultured in 2D and treated for
72 h with a drug concentration of 500 nM. 63/204 (∼30.9%)
decreased cell viability by more than 40% in at least one sample,
with a high concordance between biological replicates (Fig. 4a
and Supplementary Fig. 8A). Unsupervised hierarchical clustering
using the response data revealed that FP-RMS samples cluster
together, while FN-RMS split into two branches (Supplementary
Fig. 8B), reflecting both the different genetic landscape char-
acterizing the two RMS subtypes as well as the larger hetero-
geneity of FN-RMS tumors2. At the level of individual drugs, we
detected different response patterns. The minority of drugs
showed general toxicity including proteasome (4), HSP90 (2) and
PI3K (2) inhibitors, as well as compounds interfering with the
apoptotic machinery (YM155 and verdinexor), the dual ALK/
IGF1R inhibitor AZD3463, and the mTOR inhibitor torin 2.
Importantly however, most drugs showed more patient-specific
activity patterns. Among them, both AKT and MEK inhibitors
exhibited selective sensitivities (Fig. 4a). As proof-of-principle for
reproducibility of our discovery drug platform we generated dose-
response curves for several compounds anticipated to have either
a general (verdinexor and YM155) or specific (ponatinib, dovi-
tinib, ABT-263 and AZ20) effect and found agreement with the
predicted cell viability scores (Supplementary Fig. 9A).
To test whether drug responses differ between 2D and 3D
culture conditions, we compared the sensitivity of IC-pPDX-
35_XC and SJRHB13758_X2C cells cultured as monolayer and as
spheroids towards a selection of 12 drugs covering a broad range
of half-maximal inhibitory concentration (IC50) values. Impor-
tantly, IC50 values of the different drugs were very similar in the
two culture systems (Fig. 4B and Supplementary Fig. 9B),
suggesting that drug response is not relevantly different in 2D
and 3D cultures.
Direct culture of RMS patient cells. To move our platform
towards a co-clinical situation, we next aimed to culture cells
directly from patient tumor biopsies. For this, we isolated cells
from a lymph node biopsy removed from FP-RMS patient RMS-
ZH002 at the second relapse stage (Fig. 5a). Cultures of these cells
established in NB medium supplemented with B27 and bFGF
revealed to contain only tumor cells as determined by DNA
fluorescent in-situ hybridization using probes detecting the
FOXO1 translocation (50 out of 50 cells positive for two copies of
rearranged FOXO1) (Fig. 5b, c). We therefore performed a drug
profiling as described above, using a slightly larger drug library
containing 250 drugs (Fig. 5d). Cells from the PDX generated
from the first relapse were used as comparison. Among the
identified effective drugs were several proteasome and HDAC
inhibitors. Consequently, we validated the effects of the protea-
some inhibitor Bortezomib and the inhibitor Panabinostat alone
and in combination. The combinatorial treatment matrix revealed
IC50 values of 26 and 10 nM for Panobinostat and Bortezomib,
respectively, and showed a synergistic effect of the two drugs at
clinically relevant doses (Fig. 5e).
Taken together, this data demonstrates that the PPC drug
profiling platform is compatible with cells directly isolated from
patient tumors and allows detection of relevant patient-specific
vulnerabilities in a reasonable time frame in a co-clinical setting.
AKT is a potential therapeutic target in a subgroup of RMS. Of
particular interest among the responses detected by the drug
profiling were the individual sensitivities towards AKT and MEK
inhibitors. Correlation analysis further underscored the high
degree of overlap among different AKTi and MEKi, suggesting
on-target activities of these compounds (Supplementary Fig. 9C).
Fig. 3 Genomic and proteomic characterization of paired PDX and PPC samples. a Copy-number variant (CNV) analysis of PDXs and corresponding
PPCs (passage <11). Red arrows indicate detected copy number changes between PDX and PPC for samples where both DMEM- and NB-derived cultures
were available. b Comparison of the mutational landscape of PDXs and corresponding PPCs. The table depicts all confirmed somatic SNVs in cases with
available matched germline sequencing data. For samples without available germline data, comparison to dbSNP and 1000 g databases was used to identify
potential non-synonymous SNVs in the same genes. Focal amplifications refer to genes with more than 10 gene copies. c Principal component analysis
comparing DNA methylation profiles of RMS PDXs, PPCs and cell lines. DNA methylation data for 15 RMS PDX and PPC pairs, 9 additional PDXs and 10
cell lines were analyzed using the top 5000 most varied DNA methylation probes across all samples. Samples were indicated as color coded dots. Red and
pink denote FP PDXs and corresponding PPCs respectively; blue and brown, FN PDX and corresponding PPCs; yellow and green, additional FP and FN
PDXs; orange and purple, FP and FN cell lines. d Number of exonic SNVs in PDX and PPC model. P, PDX, C, PPC.
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Remarkably, we could discriminate three subgroups in our PPC
panel: Two groups are responsive to either AKT or ERK inhibi-
tion and a third group is refractory to both (Fig. 6a). Interestingly,
drug responses could not be predicted by the genetic profile, and
sensitive cases included both FP- and FN-RMS. In contrast,
inhibition of downstream mTOR by torin-2 showed a more
uniform toxicity (Supplementary Fig. 9D).
In order to study the interplay between the two pathways, we
next treated eight PPC cultures with a combination matrix of
afuresertib and trametinib to block both AKT and MEK,
respectively. Calculation of BLISS scores to evaluate synergism
revealed a synergistic behavior of the two drugs in all but one of
the cases, which was especially evident for the RASmutant ERMS,
with BLISS scores of 10-20 (Fig. 6b and Supplementary Fig. 10A).
IC50 values for trametinib alone differed nearly 2 logs among four
RAS mutant cases (Fig. 6c), with more sensitive cases responding
uniformly with cell death, while in the most resistant case
(SJRHB13758_X2C) up to 30 percent of the cells differentiated
(Supplementary Fig. 10B, C). IC50 of the most sensitive cases
(IC50 < 10 nM) were in the range of therapeutically applicable
concentrations. The same was the case for afuresertib (IC50 < 281
nM) and a second AKT inhibitor (GSK690693) for the most
sensitive PPCs (Fig. 6d). Western blot analysis in sensitive (IC-
pPDX-35_XC) and resistant (RMS-ZH004_XC) cases confirmed
that afuresertib selectively inhibited phosphorylation of S6
Ribosomal Protein and released a negative feedback loop on
AKT phosphorylation similar to previous reports17 (Fig. 6e and
Supplementary Fig. 11A). We also observed a strong increase in
number of floating cells as well as cleaved Caspase 3/PARP
specifically in sensitive cells (Supplementary Fig. 11B), indicating
that these cells die upon treatment.
Next, to explore the reliability of our pre-clinical in vitro platform
for prioritizing compounds, we tested the response to afuresertib
in vivo. For this, PDX from a sensitive (IC-pPDX-35_X) and a
DRUG NAME
Luminespib HSP90α/β
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Fig. 4 2D and 3D in vitro drug profiling of PPCs. a Heat map depicting the activity of indicated agents used at a final concentration of 500 nM across the
panel of RMS cells. Histological subtype, fusion status and RAS mutation status are shown above each column. Each color in the heat map indicates the
percentage of remaining cell viability after treatment relative to vehicle control: 0–30% (red), 30–60% (orange), 60–79% (light blue) and >79% (white)
(Mean; n= 2 biological replicates). b Correlation plot comparing IC50 values for indicated drugs determined in 2D and 3D cultures of IC-pPDX-35 and
SJRHB13758_X2C cells. (Mean; n= 2–3 biological replicates). Source data are provided as source data file.
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resistant (RMS-ZH004_X) patient were treated with afuresertib for
at least three consecutive treatment cycles. Strikingly, growth of the
RMS-ZH004_X tumor (Fig. 6f, lower panel) was not altered unlike
the strong response observed for IC-pPDX-35_X PDX, which
showed stable disease within the first three weeks of treatment
(Fig. 6f, upper panel). Consequently, sensitive but not resistant
tumor-bearing mice lived significantly longer than control groups
with a difference in median survival of ~19 days (Fig. 6f, right
panels). Western Blot analysis using tumor extracts after short-term
in vivo treatment (7 days) proved on-target activity of the drug
(Supplementary Fig. 11C) whereas the levels of phosphorylated S6
ribosomal protein consistently increased upon prolonged therapy,
consistent with the late-stage tumor re-growth following the strong
initial response to the drug (Supplementary Fig. 10D).
In order to further validate the combinatorial effects of AKT
and MEK inhibition in vivo, we treated IC-pPDX-35_X
tumors with the combination of afuresertib and trametinib
using low doses of both drugs. Similar to the in vitro results,
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Fig. 5 Direct culture of RMS patient cells for drug profiling and therapy guidance. a Scheme depicting the clinical course of patient RMS-ZH002.
b Bright-field image of cells isolated from the lymph node biopsy of patient RMS-ZH002. Scale bar 400 μm. The displayed image is representative of n= 1
individual cell isolation. c Fluorescence in situ hybridization detection of the FOXO1 gene using probes binding to genomic sites N- (red) and C-terminal
(green) of the gene. The displayed image is representative of n= 1 fluorescence in situ hybridization experiment. d Heat map depicting the activity of
indicated agents used at a final concentration of 500 nM on cells isolated from PDX RMS-ZH002 and on cells isolated from the lymph node biopsy. Each
color in the heat map indicates the percentage of remaining cell viability after treatment relative to vehicle control: 0–30% (red), 30–60% (orange),
60–79% (light blue) and >79% (white). e, left panel Heat map depicting effect of panobinostat and bortezomib alone and in combinations on viability of
RMS-ZH002 patient cells isolated from the lymph node biopsy (Mean; n= 2 biological replicates). Clinically applicable concentrations of the two drugs are
framed with a green box. Right panel, Heat map depicting synergism between panobinostat and bortezomib using zero interaction potency model analysis.
Source data are provided as source data file.
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In conclusion, we describe a functional and reliable proof-of-
concept drug profiling platform that allowed to identify a novel
subgroup of AKTi sensitive RMS that could not be revealed by
genomic-based predictions. These findings highlight the suit-
ability of our platform to identify functional signaling dependen-
cies in RMS.
Discussion
In the present study we have established a biobank of PDX-
derived primary rhabdomyosarcoma cultures using optimized
serum-free culture methods that preserves niche factor require-
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Our culture screen revealed a general difficulty to propagate
primary RMS cells in serum-containing media, consistent with
the low rate of success to establish cancer cell lines in the past
with standard culture protocols18. Similar results have been
documented for primary glioblastoma, neuroblastoma and ovar-
ian cancer cells, suggesting that this might be a more general
phenomenon19–21. We speculate that the multitude of compo-
nents of the serum might not properly recapitulate the fluid that
cells are exposed to in their natural milieu22. Accordingly, two out
of three serum-tolerant cultures in our cohort were associated
with a clonal outgrowth reminiscent of cell cultures undergoing
crisis before re-gaining a proliferative status19,23. The selection
pressure imposed by this culture condition resulted in the
emergence of additional genetic aberrations and, in one case, even
limited the tumorigenic potential of the cultured cells. This
occurrence resembles the loss of tumorigenicity observed in pri-
mary glioblastoma cells exposed to serum19. While future
experiments would be needed to unravel individual inhibitory
factors in serum and clarify the mechanisms of stress-induced
growth arrest, recent studies have suggested that both senescence
and differentiation can be observed20,24.
However, apart from these similarities in cell growth, a main
finding of our study is the heterogeneity among RMS PPCs at
different levels including inherent differentiation potential, cell
culture condition demands and drug response. Regarding dif-
ferentiation potential, we found that especially the two PAX7-
FOXO1-positive PPCs, but to a lesser extent also some other
PPCs, exhibited a high myogenic differentiation potential when
cultured under appropriate conditions. This suggests that pro-
differentiation strategies might be a promising therapeutic route
in these tumors. Our data also strongly suggest that specific
culture parameters have to be developed for different sarcoma
types or even subgroups within these entities. In case of two FP-
RMS, one FN-RMS and multiple osteosarcoma, none of the 18
different conditions initially tested supported growth of cells
in vitro. Interestingly, in the three RMS cases, TGFβ pathway and
ROCK inhibition allowed in vitro propagation of the cells. Ori-
ginally, ROCK inhibitors have been found to promote survival of
stem cells in in vitro cultures25 and have become part of standard
cell culture protocols for stem cells as well as cells from ecto-
dermal origin including normal epithelia and carcinoma26–28. At
this point it remains unclear whether culture dependencies reflect
cell/lineage of origin of tumors, a question that warrants further
investigations.
A second striking example of heterogeneity in culture condi-
tions was the influence of bFGF on proliferation of PPCs. While
it strongly induced proliferation of FP-RMS as anticipated,
unexpectedly half of the FN-RMS were strongly inhibited. A
similar observation has been described for Ewing cell lines where
it involved cell death after sustained activation of p38MAPK29,30.
In RMS, importance of FGFR signaling for tumorigenicity has
been described in several previous studies. In FP-RMS, FGFR4 is
a target gene of the fusion proteins and therefore highly over-
expressed, while in a subset of FN-RMS the same receptor is
activated by mutation and/or amplification31–33. Especially
mutant FGFR4 might represent a potential therapeutic target34.
Strikingly, two of the FN-RMS samples inhibited in our cohort
(diagnostic and relapse samples from the same patient) expressed
amutant FGFR4, suggesting that the signaling downstream of
the FGFRs in RMS cells is more complex than previously
appreciated and might have anti-proliferative effects under some
circumstances.
A further level of heterogeneity was detected when analyzing
drug response. Only few drugs had a general toxic effect among
PPCs, including different proteasome inhibitors or the survivin
inhibitor YM155. For many other classes of agents however, we
detected heterogeneous patterns of responses across our set of
PPCs. This resembles very well the heterogeneity of responses
seen in the clinics towards first-line therapies. Importantly, we
could demonstrate that drug sensitivities obtained from the pri-
mary 2D cultures accurately predict in vivo response. In this
context it is not surprising that we could not detect major dif-
ferences in drug response between monolayer and spheroid cul-
tures in vitro. It seems that the bulk of the cells responds similarly
in all three model systems (in vivo, in vitro in 2D and 3D). This
might be surprising taking into account the large efforts that are
undertaken to develop 3D model systems for drug screenings,
especially for carcinoma. However, they are in agreement with
similar 2D screening approaches, which have resulted in identi-
fication of cancer specific vulnerabilities in adult cancers8.
Additional work will be necessary to evaluate whether 3D models
offer an additional benefit measuring drug responses in specific
cellular subpopulations, such as the tumor promoting compart-
ment in FN-RMS tumors35–37. Taken together, heterogeneity at
Fig. 6 In vitro and in vivo validation of afuresertib and trametinib for RMS treatment. a Comparative analysis of afuresertib (AKTi, blue) and BI-847325
(MEKi, red) effects on cell viability. Data were computed from the drug screen experiments. Gray and white areas indicate the range below and
above 50 percent inhibition of cell viability, respectively, which were chosen as range of high and low drug response (Mean; n= 2 biological replicates).
b BLISS synergy scores from the combination treatment of indicated cells treated with a combination matrix of afuresertib and trametinib (Mean with
range; n= 2 biological replicates). Scores were determined with the synergyfinder webtool. c Cell viability of indicated PPCs treated for 72 h with increasing
concentrations of the MEK inhibitor trametinib. RAS mutant samples are depicted in colors, RAS wild type samples are in gray. (Mean; n= 2 biological
replicates). d Cell viability of indicated PPCs treated for 72 h with increasing concentrations of the AKT inhibitors afuresertib (left panel) and GSK690693
(right panel). (RMS-ZH004_XC and IC-pPDX-35_XC, mean ± range, n= 2 biological replicates; SJRHB13758_X2C, SJRHB010463_X16C and
SJRHB013759_X1C, mean ± sd, n= 3 biological replicates). e Western blot analysis showing expression and phosporylation status of indicated proteins
from PPCs treated for 2.5 h with afuresertib at 200 nM and 600 nM or DMSO as control. Both an afuresertib-sensitive (IC-pPDX-35_XC) and -resistant
(RMS-ZH004_XC) case is presented. GAPDH was used as loading control. The displayed blots are representative of n= 2 independent experiments.
f, upper left panel Tumor growth of IC-pPDX-35 PDX (sensitive) treated with 100mg/kg per day of afuresertib (green line) or vehicle control (black line).
Gray color depicts treatment time frame (5 days) for four consecutive treatment cycles. (Mean ± sem; n= 6 mice; two-way ANOVA). d, Upper right panel,
Kaplan–Mayer curves of mice from left panel. (Log rank (Mantel-Cox) test). f, Lower left panel, Tumor growth of RMS-ZH004 PDX (resistant) following
the same treatment schedule as in the upper panel but for three consecutive cycles. (Mean ± sem; n= 6 mice; two-way ANOVA; NS, not significant).
(Lower right panel) Survival curve of mice from left panel. (Log rank (Mantel-Cox) test; NS, not significant). g Tumor growth of IC-pPDX-35_XC PDX
treated with vehicle controls (black line), 20mg/kg per day of afuresertib (red line), 0.5 mg/kg per day of trametinib (dark blue line) or the combination of
the two drugs (light blue line). Gray color depicts treatment time frame (5 days) for three consecutive treatment cycles. (Mean ± sem; control and
afuresertib, n= 5 mice; trametinib, n= 4 mice; combination, n= 3 mice; two-way ANOVA with Tukey’s multiple comparisons test). Source data are
provided as source data file.
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different levels strongly argues for a functional precision medicine
approach and might be taken into account in screening programs
using a fixed number of models38. Importantly, experimental-
designs using one mouse per tumor have been proposed as
approach to test a large number of different tumors in vivo in
parallel39.
Among the most interesting drug sensitivities were extra-
ordinary patient-specific sensitivities towards AKTi and MEKi
that could not be predicted by genomic data. AKTi are currently
developed in phase I/II clinical trials for adult malignancies40.
Despite some evidence suggesting that AKT phosphorylation
(AKT Ser473) predicts poor overall survival in RMS, little
attention has been drawn on blockade of the AKT/mTOR axis so
far41. Our search for potential biomarkers of these drug sensi-
tivities failed to identify a close relationship between genomic
features and drug responses. Instead, our findings indicate that
in vitro drug profiling on PPCs is predictive of the response of the
parental PDX and therefore is a suitable approach to pre-select
RMS sub-groups who may benefit from anti-AKT therapies.
Finally, we also demonstrated that the optimized culture con-
ditions allow culture of cells directly isolated from patient tumors.
Circumventing the PDX generation has the advantage that the
procedure is potentially significantly accelerated. Time until drug
profiling is of vital importance, especially in the relapse situation
when standard therapies are not effective anymore. Amount and
quality of material available for isolation of the cells is an
important parameter for this approach.
Overall, our findings provide important groundwork for a
clinically used drug screening platform for sarcoma with the aim
to offer drug response profiling as tool for therapeutic decisions
for individual patients in the clinics.
Methods
Patient consent and sample collection. All patients gave written informed
consent at the participating institutions. This includes general informed consent
from TATA Memorial Hospital and patient consents from University Children’s
Hospital Zurich, Emma Children’s Hospital Amsterdam and Institut Curie Paris.
Orthothopic PDX models from St Jude Children’s Hospital were obtained through
Childhood Solid Tumor Network42, for which patient consent has been published
previously6. Fresh biopsy material from human tumors was frozen in DMEM
supplemented with 10% FBS and 10% DMSO at −80 °C in a cell freezing container
before shipment to the the site of transplantation took place.
PDX transplantation. For tumor amplification, pieces with a size of ~10–30 mm3
from fresh human tumor biopsis or established PDX tumors were transplanted
subcutaneously into the flank of 6–10 weeks old, sex-matched NOD scid gamma
(NSG) mice. Engraftment of tumors was monitored by tumor size measurements
three times a week using a caliper. Tumors were isolated when they reached a size
of ~1000 mm3.
For in vivo drug treatment, a single cell suspension of dissociated PDX tumors
containing 0.7–5 × 106 cells was injected subcutaneously into the flank of sex
matched, 6–10 weeks old NSG mice. A description of the PDX lines used in this
study can be found in Supplementary Fig. 1A.
Isolation of PDX cells. PDX tumors freshly isolated from mice were first minced
using two scalpels and then incubated in a dissociation buffer composed of 200 μg/
ml liberase DH (Roche, 5401054001), 0.1 mg/ml DNase I (StemCell, #07900) and
1 mM MgCl2 in 1x HBSS buffer (Sigma, H6648) for 30–60 min at 37 °C. When the
tumor cell suspension was pipettable through a 1 ml tip, digestion was stopped with
serum containing medium and remaining tumor pieces were removed by filtration
through a 70μm cell strainer. Cell suspensions were then washed with PBS and
either directly used for cell culture or frozen in freezing medium (CryoStor CS10,
StemCell, #07930) for future use.
Culture of PDX cells. Media used for culture of PDX cells included DMEM
(Sigma, D5671) or F10 (Life technologies, 11550-043) both supplemented with 10%
heat inactivated FBS (Thermofisher Scientific), NB medium (Thermofisher Scien-
tific, 21103049), supplemented with 2xB-27 (Thermofisher Scientific, 17504044),
and Advanced DMEM/F12 (Thermofisher Scientific,12634010), supplemented with
1× or 2× (for drug screening) B-27, 1.25 mM N-acetyl-L-cysteine (Sigma-Aldrich,
A9165), 5 μM A83-01 (Tocris Bioscience, 2939), and 10 μM Y-27632 (Abmole
Bioscience, M1817). All media were further supplemented with 100 U/ml
penicillin/streptomycin and 2 mM glutamax (Life technologies, 35050-061). When
indicated, media were further supplemented with 20 ng/ml bFGF (PeproTech, AF-
100-18B) and 20 ng/ml EGF (PeproTech, AF-100-15). Three times per week, 75%
of medium was replaced with fresh one. When reaching confluency, cells were
detached using Accutase (Sigma-Aldrich, A6964) and splitted in a ratio of 1:2
to 1:3.
For Matrigel-coating, Matrigel (Corning, 354234) was diluted 1:10 in NB
medium and left on the dish for 30–60 min at RT. Before cell-plating, excess
Matrigel solution was removed. For Gelatin-coating, a 2% solution of Gelatin
(Sigma-Aldrich, G9391) in water was left on the dish for 2 h at 37 °C. The solution
was then removed and the plates were dried at RT for 30–60 min.
For spheroid culture, 5000 (SJRHB13758_X2C) or 10‘000 (IC-pPDX-35_XC)
cells were plated per 96 well in round bottom cell repellent plates (Greiner Bio-
One, 650970) in NB medium supplemented with Matrigel (1:50). Half of the
medium was changed three times a week.
Culture condition optimization. 30‘000 cells freshly isolated from PDX tumors
were plated per 96 well in the different test media. When cells reached confluency
in one well, representative phase contrast pictures were taken from each condition,
before cell viability was measured by WST-1 assay. The same plate was then used
for immunofluorescence detection of myosin heavy chain (MHC) and quantifi-
cation of mouse stroma cells by DAPI staining.
Quantification of mouse cells. For quantification of mouse stroma cells con-
taminating PPC cultures, cells isolated from PDX and grown under different
conditions in 96 well plates were stained with DAPI. Mouse cells were then
identified on microscopic images by the punctate DAPI-staining pattern of their
nuclei. Relative numbers of human and mouse cells were determined on micro-
scopic images containing at least 200 cells of possible.
Immunofluorescence. Immunofluorescence was performed in 96 well plates. Cells
were first fixed with 4% paraformaldehyde for 15 min, followed by quenching with
0.1 M glycine in PBS for 5 min and permeabilization with 0.1% Triton-X 100 in
PBS for 15 min. After blocking with 4% horse serum in 0.1 % Triton-X 100 in PBS,
cells were incubated with primary antibody diluted in the same buffer at 4 °C over
night in a humid chamber. After three washings with PBS for 5 min, cells were
incubated with secondary antibody diluted in PBS with 4% horse serum for 1 h. A
monoclonal anti-MHC antibody (MF 20; Developmental Studies Hybridoma Bank,
Iowa) (1:500) and an Alexa 594-labeled donkey anti-mouse secondary Ab (Ther-
mofisher Scientific, A11032) (1:500) were used. For nuclear staining, cells were
covered with PBS containing 10 μg/ml DAPI and analyzed by fluorescence
microscopy.
Immunohistochemical staining of spheroids and tumor sections. 2 μm sections
of formalin-fixed, paraffin-embedded (FFPE) spheroids or tumor tissues were
stained on the Bond automated staining system (Leica). For epitope retrievel, slides
were first either enzymatically predigested with Ventana protease 1 for 10 min
(Desmin) or heated in Epitope retrieval solution from Leica Bond system (PH9) to
100 °C for 20 min (Myogenin), 30 min (AP2b and Glu-1) or 45 min (cleaved
Caspase-3). The sections were then incubated for 30 min with primary antibodies
against Desmin (Novocastra Laboratories Ltd, NCL-L-DES-DERII) (1:200), Myo-
genin (Cell Marque Lifescreen 296M-14Ltd) (1:100), AP2b (Santa Cruz, H-87)
(1:400), cleaved Caspase-3 (Cell Signaling Technology, #9661) (1:500) and Glut-1
(Cell Marque Lifescreen Ltd., CMC35511020) (1:300). Visualization of the anti-
bodies was performed with a Bond refine detection system, Leica. All sections were
counterstained with haematoxylin.
Measurement of long-term proliferation of cells. Cells were cultured in parallel
under optimal conditions as determined by condition screening and in conven-
tional DMEM supplemented with FBS. Cell numbers were counted at each passage.
Drug profiling. For drug profiling, 3000–20,000 PPCs in NB medium in most cases
supplemented with bFGF and EGF were plated per 384 well coated with Matrigel
or Gelatin. Only the GF-sensitive PPC (SJRHB012_YC, SJRHB012_ZC,
SJRHB011_XC and SJRHB011_YC) were cultured in absence of bFGF and EGF.
For drug screen in cell lines, 2000-4000 cells were seeded in NB medium supple-
mented with bFGF and EGF and in absence of any substratum. The next day,
medium was changed and cells were incubated with a drug library containing 204
different drugs (Selleckchem) in a concentration of 500 nM in duplicate wells for
72 h. 12 wells treated with DMSO on each plate served as controls. Cell viability
was then determined by WST-1 assay (Roche, 11644807001). A list of compounds
employed in this study is provided in Supplementary table 2.
Drug response curves. For IC50 determination in 2D cultures, 3000–20,000 PDX
cells were plated in NB medium supplemented with bFGF and EGF per 384 well
(unless otherwise specified) coated with Matrigel or Gelatin. The next day, medium
was changed and cells were incubated with drug in a logarithmic concentration
range between 0.006–10 μM using a digital dispenser (HP D300). After 72 h cell
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viability was measured by WST-1 assay or CellTiter-Glo 3D assay (Promega,
G9681) when compared to 3D cultures. For drug test in 3D cultures, cells were
cultured as spheroids in 96 well plates for 7 days as described above. Spheroids
were then treated and incubated as above and cell viability was measured using the
CellTiter-Glo3D assay.
Caspase 3/7-activity assay. Cells were seeded in white 384-well plates with clear
bottom (Greiner Bio-One, #781098). Caspase activity was determined at indicated
time points by Caspase-Glo 3/7 Assay (Promega, #G8093) according to the
manufacturer’s instructions. Luminescence was measured using the multidetection
microplate reader Synergy HT (Bio-Tek Instruments).
High throughput microscopy. An Operetta high content screening system was
used for high throughput analysis of cells immunofluorescently stained for myosin
heavy chain. Identification and quantification of myosin heavy chain positive cells
was performed with the Harmony software.
In vivo drug treatment. Tumors were established from dissociated PDX and
tumor harboring mice were randomized into treatment and control cohorts of 6
animals when the tumor average size reached about 100 mm3 (single afuresertib
experiment) or individually distributed into different treatment groups when
tumors reached about 100 mm3 (combination experiment). For afuresertib treat-
ment, drug (100 or 20 mg/kg) and vehicle were administered by oral gavage 5 times
a week. Afuresertib (Selleck, S7521) was dissolved in 20% PEG-400 (Lipoid), 1%
DMSO and 79% H2O. For trametinib (ApexBio, A3018) treatment, drug (0.5 mg/
kg) was dissolved in 4% DMSO/ corn oil and administered by i.p. injection five
times a week. Tumor size was measured three times a week using a caliper and
mouse weight was measured twice a week. No mice needed to be euthanized due to
severe body weight loss (>20% than baseline).
Western blot. Cell lysates for Western Blots were generated using RIPA buffer
(50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 1 mM
EGTA, 0.1% SDS, 50 mM NaF, 10 mM sodium β-glycerolphosphate, 5 mM sodium
pyrophosphate, 1 mM sodium orthovanadate), and supplemented with Complete
Mini Protease Inhibitor cocktail (Sigma-Aldrich, # 11697498001). Proteins were
separated using NuPAGE™ Novex™ 4-12% Bis-Tris gels (ThermoFisher) and
transferred to nitrocellulose membranes (GE Healthcare Life Sciences) by wet-
blotting. Membranes were then blocked with 5% milk or BSA in TBS/0.05% tween
for 20 min, followed by incubation with the primary antibody overnight at 4 °C.
After three washing steps with TBS-0.05% tween for 5 min, membranes were
incubated with a horseradish peroxidase-linked secondary antibody for 1 h at RT.
After three additional washing steps with TBS/0.05% tween for 5 min and one final
wash step with PBS for 1 min, proteins were detected by chemiluminescence using
either the Pierce™ ECL or the Supersignal Western blotting reagent (both Ther-
moFisher) and a ChemiDoc MP imager (BioRad). Antibodies used included the
following ones from Cell Signaling: anti-phospho-mTOR (#2971), anti-mTOR
(#2983), anti-phospho-S6 ribosomal protein (#2211), anti-S6 ribosomal protein
(#2217), anti-phospho-AKT Thr308 (#9275), anti-phospho-Akt Ser473 (#9271),
anti-AKT (#9272), anti-GAPDH (#2118), anti-PARP (#9542), anti-cleaved CAS-
PASE 3 (#9664). Antibodies against P53 was purchased from ThermoFisher Sci-
entific (#AHO0152) and against FOXO1 from Santa Cruz Biotechnology (sc-
11350). All primary antibodies were diluted 1:1000 in milk. For secondary anti-
bodies, HRP-linked anti-mouse IgG (Cell Signaling, #7076) and HRP-linked anti-
rabbit IgG (Cell Signaling, #7074) were used at 1:5000 dilution in milk.
DNA copy number analysis. Genomic DNA was extracted from PDX pieces or
cultured cells using the DNAse® Blood&Tissue Kit (Qiagen, #69506) following the
manufacturer’s instructions. The aCGH assay was performed using the CytoScan™
HD Array Kit according to the manufacturer’s protocol (Affymetrix, Thermo
Fisher Scientific, MA, USA). The raw data of each single sample was analyzed with
the Chromosome Analysis Suite (ChAS) software (Version 3.1.1.27, Affymetrix).
Exome sequencing and analysis. DNA was isolated from PDX and PPCs using
the Qiagen DNeasy Kit. For exome sequencing, exome enrichment was performed
using the Agilent SureSelectXT Human All Exon V6 kit. Paired-end sequencing
was performed using the Illumina system. The sequences were demultiplexed using
bcl2fasta in the illumina CASAVA pipeline to get fastq files. For processing of the
data, the whole exome sequencing pipeline web tool was used43. This included the
bwa tool (0.7.10) for alignment of the sequences with the human genome, Picard
(1.119) for duplicate removal and GATK (2.8-1) with the GATK algorithm for
calling of SNVs and insertion/deletions. Variants were further filtered using the
following criteria: Coverage ≥10, ambiguous mappings per variant ≤5, Phred-scaled
consensus quality ≥50, variant confidence quality ≥1.5, strand bias Fisher exact test
≤60, not present in dbSNP, not present in 1000 g (minor allele frequency <0.01).
Genewise target coverage data was used to identify amplified genes, using a
threshold of 10 fold43.
Genome-wide DNA-methylation analysis. Genomic DNA from eight PDX/PPC
pairs was treated with bisulfite (EZ-96 DNA Methylation Kit [Zymo Research])44,
and then DNA methylation was analyzed on the Infinium MethylationEPIC
(EPIC) BeadChip (Illumina). In addition, DNA methylation data from 12 RMS
PDXs and 10 conventional RMS cell lines previously generated on the Infinium
HumanMethylation450 (HM450) BeadChip were included in this analysis. Raw
IDAT files from both sources were processed and normalized using the noob
method in the minfi package45,46. Only probes that overlapped between EPIC and
HM450 were studied in this analysis. Probes with detection P-value >0.01 in at least
one sample, probes located on X and Y chromosome, non-CpG probes, probes
containing a SNP at the single-base extension or CpG site, probes with genetic
variants overlapping the body of the probes and probes identified as cross-
hybridizing were discarded47. The β-value was computed as the measure of
methylation, ranging from 0 (completely unmethylated) to 1.0 (complete methy-
lated methylated). Hierarchical clustering and principal component analyses were
performed as described44. Heatmaps were generated using the heatmap.plus
packages in R. Principal component analysis was applied using prcomp function in
stats package.
Fluorescence in situ hybridization. Cells cultured on chamber slides were fixed
with Methanol-Acetic acid (3:1) for 10 min at −20 °C. FISH evaluation of FOXO1
rearrangement was performed with the FOXO1 break-apart probe (Cytocell,
Cambridge, U.K.) according to the instructions of the manufacturer. Briefly, slide
and probe were co-denatured at 80 °C for 2 min, followed by overnight hybridi-
zation at 37 °C and humid conditions using a Leica ThermoBrite (Biosystems
Switzerland AG, Muttenz, Switzerland). Then, the slides were washed in a 0.4x
saline sodium citrate (SSC) / 0.3% (vol/vol) IGEPAL solution (Sigma-Aldrich) for
2 min at 72 °C, followed by 1 min in a 2× SSC / 0.1 % (vol/vol) IGEPAL solution at
room temperature. The slides were air dried, and the nuclei were counterstained
with Vectashield Mounting Medium containing DAPI (REACTOLAB S.A., Ser-
vion, Switzerland). Microscopic images were acquired using the Axio Imager.Z2
microscope (Carl Zeiss AG, Feldbach, Switzerland) and 50 nuclei were analyzed
using the Isis software (MetaSystems Hard & Software GmbH, Altlussheim,
Germany).
Unsupervised hierarchical clustering. Unsupervised two-way hierarchical clus-
tering was done with the software D-chip.
Statistics. Data analysis was performed using GraphPad Prism (version 8). Sta-
tistic tests and number of biological replicates (N) per each experiment are outlined
in figure legends. Synergism was determined using the Synergyfinder webtool
(https://synergyfinder.fimm.fi).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The exome seq, array CGH and DNA methylation data has been deposited in the
database of genotypes and phenotypes (dbGaP) under the accession code phs002051.v1.
p1. All numerical data underlying Figs. 1–6 and Supplementary Figs. 1–11 are provided
as a source data file. All the other data supporting the findings of this study are available
within the article and its supplementary information files and from the corresponding
author upon reasonable request. A reporting summary for this article is available as a
supplementary information file. PPCs can be obtained from the corresponding author
through an MTA. All data associated with this study are present in the paper or the
Supplementary Materials. Source data are provided with this paper.
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